Dolby Laboratories (NYSE:DLB) Stock Bumped Up to Buy by Wall Street Zen

Dolby Laboratories (NYSE:DLB – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts have also issued reports on the stock. Rosenblatt Securities decreased their price target on shares of Dolby Laboratories from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, November 16th. Weiss Ratings raised shares of Dolby Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, September 9th. Zacks Research raised shares of Dolby Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, November 13th. Finally, Robert W. Baird cut their target price on shares of Dolby Laboratories from $62.00 to $60.00 and set a “neutral” rating on the stock in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Dolby Laboratories has an average rating of “Hold” and a consensus price target of $76.67.

Read Our Latest Research Report on DLB

Dolby Laboratories Stock Up 0.8%

NYSE:DLB opened at $55.22 on Friday. Dolby Laboratories has a twelve month low of $48.26 and a twelve month high of $69.95. The stock’s 50-day simple moving average is $60.46 and its 200 day simple moving average is $59.29. The firm has a market capitalization of $5.17 billion, a PE ratio of 20.45 and a beta of 0.79.

Dolby Laboratories (NYSE:DLB – Get Free Report) last issued its earnings results on Tuesday, November 17th. The electronics maker reported $1.25 EPS for the quarter, topping the consensus estimate of $1.20 by $0.05. The firm had revenue of $373.54 million during the quarter, compared to the consensus estimate of $372.76 million. Dolby Laboratories had a return on equity of 11.08% and a net margin of 16.70%. The business’s quarterly revenue was up 21.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.99 earnings per share. Dolby Laboratories has set its Q1 2027 guidance at 0.410-0.560 EPS and its FY 2027 guidance at 4.270-4.420 EPS. On average, analysts anticipate that Dolby Laboratories will post 3.36 EPS for the current fiscal year.

Dolby Laboratories announced that its board has approved a stock repurchase program on Thursday, July 30th that allows the company to buy back $350 million in shares. This buyback authorization allows the electronics maker to buy up to 7% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Dolby Laboratories

In other Dolby Laboratories news, CAO Ryan Nicholson sold 1,183 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $65.28, for a total transaction of $77,226.24. Following the sale, the chief accounting officer directly owned 34,453 shares of the company’s stock, valued at $2,249,091.84. The trade was a 3.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP John Couling sold 7,667 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $58.78, for a total transaction of $450,666.26. Following the sale, the senior vice president directly owned 166,803 shares in the company, valued at $9,804,680.34. The trade was a 4.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 16,517 shares of company stock worth $995,963. 37.93% of the stock is owned by corporate insiders.

Institutional Trading of Dolby Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new position in Dolby Laboratories during the 2nd quarter worth about $253,289,000. First Trust Advisors LP raised its position in shares of Dolby Laboratories by 6.2% during the third quarter. First Trust Advisors LP now owns 2,872,446 shares of the electronics maker’s stock worth $168,814,000 after acquiring an additional 166,942 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Dolby Laboratories by 6.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,321,407 shares of the electronics maker’s stock worth $79,357,000 after acquiring an additional 83,835 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC bought a new position in shares of Dolby Laboratories during the third quarter worth about $40,429,000. Finally, Advisors Asset Management Inc. acquired a new position in shares of Dolby Laboratories in the third quarter worth approximately $34,670,000. 58.56% of the stock is currently owned by institutional investors and hedge funds.

About Dolby Laboratories

(Get Free Report)

Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.

See Also

Analyst Recommendations for Dolby Laboratories (NYSE:DLB)

Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.